Terms: = Ovarian cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Staging
20 results:
1. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
2. Primary Breast Carcinoma of the Vulva Metastatic to Lymph Nodes and Bones: A Case Report and Literature Review.
Ananthula A; Lockwood B; Savage J; Malak S; Chen C; Makhoul I; Pennisi A
Perm J; 2020; 24():. PubMed ID: 32097114
[TBL] [Abstract] [Full Text] [Related]
3. Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
Rodriguez-Velazquez A; Velez R; Lafontaine JC; Colon-Echevarria CB; Lamboy-Caraballo RD; Ramirez I; Mendoza A; Casbas-Hernandez P; Armaiz-Pena GN
BMC Cancer; 2018 Nov; 18(1):1177. PubMed ID: 30482165
[TBL] [Abstract] [Full Text] [Related]
4. Is Estradiol Monitoring Necessary in Women Receiving ovarian Suppression for Breast cancer?
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
J Clin Oncol; 2016 May; 34(14):1573-9. PubMed ID: 26951320
[TBL] [Abstract] [Full Text] [Related]
5. Expressions of fatty acid synthase and her2 are correlated with poor prognosis of ovarian cancer.
Cai Y; Wang J; Zhang L; Wu D; Yu D; Tian X; Liu J; Jiang X; Shen Y; Zhang L; Ren M; Huang P
Med Oncol; 2015 Jan; 32(1):391. PubMed ID: 25433947
[TBL] [Abstract] [Full Text] [Related]
6. her-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.
Kalogiannidis I; Petousis S; Bobos M; Margioula-Siarkou C; Topalidou M; Papanikolaou A; Vergote I; Agorastos T
Arch Gynecol Obstet; 2014 Dec; 290(6):1231-7. PubMed ID: 25022554
[TBL] [Abstract] [Full Text] [Related]
7. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases.
Lecarpentier E; Ouaffi L; Mir O; Berveiller P; Maurel M; Pujade-Lauraine E; Bouillot JL; Veyrie N
Invest New Drugs; 2011 Dec; 29(6):1500-3. PubMed ID: 20676743
[TBL] [Abstract] [Full Text] [Related]
8. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract] [Full Text] [Related]
9. [Primary fallopian tube carcinoma].
Mladenović-Segedi L
Med Pregl; 2009; 62(1-2):31-6. PubMed ID: 19514598
[TBL] [Abstract] [Full Text] [Related]
10. Quantitative immuno-positron emission tomography imaging of her2-positive tumor xenografts with an iodine-124 labeled anti-her2 diabody.
Robinson MK; Doss M; Shaller C; Narayanan D; Marks JD; Adler LP; González Trotter DE; Adams GP
Cancer Res; 2005 Feb; 65(4):1471-8. PubMed ID: 15735035
[TBL] [Abstract] [Full Text] [Related]
11. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.
Skírnisdóttir I; Seidal T; Karlsson MG; Sorbe B
Int J Oncol; 2005 Jan; 26(1):177-83. PubMed ID: 15586238
[TBL] [Abstract] [Full Text] [Related]
12. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract] [Full Text] [Related]
13. FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples.
Kato H; Arakawa A; Suzumori K; Kataoka N; Young SR
Exp Mol Pathol; 2004 Apr; 76(2):138-42. PubMed ID: 15010292
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer.
Fanning J; Brown S; Phibbs G; Kramer T; Zaher A
Int J Gynecol Cancer; 2002; 12(3):286-9. PubMed ID: 12060450
[TBL] [Abstract] [Full Text] [Related]
15. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.
Nijman HW; van Diest PJ; Poort-Keesom RJ; von Mensdorff-Pouilly S; Verstraeten RA; Kummer A; Meijer CJ; Melief CJ; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 2001 Jan; 94(1):114-20. PubMed ID: 11134836
[TBL] [Abstract] [Full Text] [Related]
16. her-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract] [Full Text] [Related]
17. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract] [Full Text] [Related]
18. [Value of prognostic factors in early stage ovarian carcinoma].
Sevelda P
Zentralbl Gynakol; 1996; 118(6):326-9. PubMed ID: 8768008
[TBL] [Abstract] [Full Text] [Related]
19. Prevalence and significance of her-2/neu expression in early epithelial ovarian cancer.
Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
[TBL] [Abstract] [Full Text] [Related]
20. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract] [Full Text] [Related]
